한국맥널티
Financials
Valuation Metrics
한국맥널티's Market Cap is ₩188B. At end of 2025 it was ₩357B. Ranked #2309 of 2,410 in KR market (top 96%), #1544 of 1,631 on KOSDAQ (top 95%), #79 of 82 in Food, Beverage & Tobacco (top 96%) by Market Cap.
Investment Metrics(as of 2026-11-02)
| Metric | Value | Rank |
|---|---|---|
| Size | ||
| Market Cap | 18.84B KRW | KR#2,309/2,410 Sec#79/82 |
| Revenue | 97.26B KRW | KR#1,432/2,410 Sec#65/82 |
| Net Income | -784.8M KRW | KR—/2,410 Sec—/82 |
| Total Assets | 103.10B KRW | KR#1,752/2,410 Sec#71/82 |
| Net Assets | 46.11B KRW | KR#1,957/2,410 Sec#70/82 |
| Employees | 114 | KR#1,538/2,410 Sec#59/82 |
| Value | ||
| P/B | 0.41x | KR#681/2,410 Sec#41/82 |
| P/S | 0.19x | KR#403/2,410 Sec#37/82 |
| FCF Yield | 26.54% | KR#247/2,410 Sec#27/82 |
| Profitability | ||
| ROE | -1.70% | KR#1,665/2,410 Sec#55/82 |
| ROA | -0.76% | KR#1,643/2,410 Sec#55/82 |
| Op. Margin | -1.25% | KR#1,697/2,410 Sec#73/82 |
| Revenue Growth | 3.89% | KR#1,265/2,410 Sec#36/82 |
| Financial Health | ||
| Debt Ratio | 123.58% | KR#1,735/2,410 Sec#45/82 |
| Total Debt | 42.12B KRW | KR#1,067/2,410 Sec#56/82 |
| FCF | 5.00B KRW | KR#906/2,410 Sec#48/82 |
| Cash | 6.32B KRW | KR#1,913/2,410 Sec#70/82 |
| Current Ratio | 1.33x | KR#1,341/2,410 Sec#33/82 |
| Dividend | ||
| Div. Yield | 0.82% | KR#1,191/2,410 Sec#60/82 |
| Div. Growth | 0.00% | KR—/2,410 Sec—/82 |
| Performance | ||
| 1Y Return | -51.59% | KR#1,993/2,410 Sec#76/82 |
| 1M Return | -19.20% | KR#2,039/2,410 Sec#80/82 |
| From 52W High | -53.43% | KR#1,324/2,410 Sec#66/82 |
| 1Y MDD | -53.77% | KR#1,123/2,410 Sec#64/82 |
| Trading | ||
| Volume | 15,965 shares | KR#1,963/2,410 Sec#53/82 |
| Trading Value | 27.1M KRW | KR#2,161/2,410 Sec#72/82 |
| Foreign Own. | 1.82% | KR#1,688/2,410 Sec#62/82 |
| Per Share | ||
| EPS | -71 KRW | KR—/2,410 Sec—/82 |
| BPS | 4,180 KRW | KR#1,646/2,410 Sec#63/82 |
Company Info
Korea McNulty, established in 1997 and headquartered in Cheonan, Chungcheongnam-do, primarily engages in coffee manufacturing and processing. In 2020, it spun off its pharmaceutical business, establishing McNulty Pharm Co., Ltd. and McNulty Bio Co., Ltd. as affiliates. The company's coffee division covers the entire process from green beans to roasted coffee products, while its pharmaceutical division produces general and specialized pharmaceuticals, alongside CMO and CSO services. Korea McNulty is expanding its business by entering large distribution channels, increasing B2B sales, launching a coffee academy, and pursuing the conversion of its Chinese sales subsidiary.